SAN JOSE, Calif., Dec. 1, 2025 — Mixx Technologies, the innovator behind high-performance, system-scale optical connectivity for artificial intelligence (AI) infrastructure, today announced the successful closure of a $33 million Series A funding round. The financing was led by ICM HPQC Fund, with participation from TDK Ventures, Systemiq Capital, Banpu Innovation & Ventures, G Vision Capital, Ajinomoto Group Ventures, AVITIC Innovation Fund, and other strategic partners. The oversubscribed round reflects strong investor confidence in Mixx’s breakthrough approach.

Mixx was founded by the innovators behind Intel’s silicon photonics-based transceivers and Broadcom’s industry-first co-packaged optics (CPO) for network switches. The team has been at the forefront of every major leap in connectivity and is now uniting to eliminate the interconnect bottleneck that constrains performance and scalability of artificial intelligence. With a platform that merges photonics, advanced packaging, and system architecture, Mixx is building the foundation for faster and more parallelized AI infrastructure.

The capital will be used to advance Mixx’s product development milestones, expand its global footprint with R&D centers and ecosystem partnership in the U.S., India, and Taiwan.

“As AI infrastructure scales into the exabyte era, the very metrics of performance are shifting,” said Vivek Raghuraman, CEO and co-founder of Mixx Technologies. “What once centered on link speeds and component efficiency must now account for system-wide power, latency, and reliability measured at the data center level. Mixx is rethinking these fundamentals to optimize end-to-end data movement, where every picojoule saved and nanosecond gained compounds across trillions of interconnected nodes.”

At the heart of this shift is HBxIO™, our silicon-integrated optical engine that forms a communication platform for next-generation AI infrastructure. Combined with open standards, proprietary orchestration algorithms, and a high-radix connector, this advanced architecture bridges the compute demands of the back-end and front-end network with unprecedented speed and reliability. By delivering higher bandwidth, lower power consumption, and reduced total cost of ownership, Mixx is redefining the connectivity fabric needed to realize the full potential of tomorrow’s intelligent systems.

About Mixx Technologies

Mixx Technologies, Inc. is a deep-tech company solving the data-movement bottleneck for AI infrastructure. Mixx’s foundational multi-terabit HBxIO™ platform provides ultra-high-radix, scale-up connectivity enabling cloud service providers to deploy massive AI inference models at unprecedented speed and efficiency. Headquartered in San Jose, California, with operations in India and Taiwan, Mixx Technologies is driving the next generation of reliable, scalable and sustainable AI infrastructure.

SOURCE Mixx Technologies, Inc

Financing accelerates clinical validation and commercial readiness, as circular RNAs emerge as a new category of brain-derived blood biomarkers with best-in-class performance

SAN DIEGO, Dec. 1, 2025 — Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and psychiatry, today announced the successful closure of a $15 million Series A financing round. The financing was led by Mountain Group Partners, with participation from Poplar Grove Investors, HIP Fund, and the Alzheimer’s Drug Discovery Foundation (ADDF). This transformative capital will accelerate the clinical development and commercialization of Circular Genomics’ proprietary circRNA biomarker platform for the early detection of Alzheimer’s disease (AD), advancing the company’s mission to reshape the standard of care for all neurological disorders.

“This Series A financing represents a pivotal milestone in our journey to transform precision neurology, including Alzheimer’s disease diagnosis and patient care,” said Paul Sargeant, Chief Executive Officer of Circular Genomics. “The strong support from our world-class investors validates the breakthrough potential of our circular RNA platform and underscores the urgent need for accessible, comprehensive blood-based biomarkers that can detect Alzheimer’s biology at the earliest stages. With this capital, we are positioned to advance our clinical programs, expand our world-class team, and bring our first transformative test in Alzheimer’s disease to patients and physicians who desperately need better diagnostic tools.”

The Series A proceeds will be deployed strategically to advance multiple high-priority initiatives:

• Clinical Validation: Expanding clinical validation studies to demonstrate the platform’s utility across diverse patient populations and healthcare settings
• Platform Innovation: Enhancing the circRNA biomarker platform to expand beyond Alzheimer’s disease into other neurodegenerative and psychiatric disorders
• Strategic Partnerships: Establishing collaborations with leading academic institutions, pharmaceutical companies, and diagnostic service providers
• Team Expansion: Recruiting world-class talent across clinical development, regulatory affairs, commercial operations, and scientific research

The Unmet Need for Early Alzheimer’s Detection

Alzheimer’s disease affects more than 7 million Americans, with diagnosis often delayed by 2-3 years after symptom onset. It is the most prevalent type of dementia, accounting for up to 80% of all dementia cases, making it the leading cause of cognitive decline among older adults. Despite this prominence, approximately 75% of all dementia cases go undiagnosed, and among patients with diagnosed dementia, roughly 50% receive no formal diagnosis. Traditional diagnostic methods, including PET imaging and cerebrospinal fluid testing, are expensive, invasive, and not widely accessible. The recent approval of disease-modifying therapies has created an unprecedented urgency for accurate, accessible blood-based biomarkers that can identify patients at the earliest disease stages—when interventions may have the most profound impact on disease trajectory.

A Transformative Solution: Circular RNA as a New Class of Blood Biomarkers

Alzheimer’s disease is now recognized as a biologically detectable condition long before clinical symptoms appear—yet current diagnostic solutions face significant limitations in accessibility, specificity, and pathway-level resolution. Despite recent advances, there remains a critical need for biomarkers that capture the full complexity of disrupted molecular pathways driving AD pathogenesis.

Circular Genomics’ circRNA platform directly addresses this gap.  Circular RNAs—highly stable, brain-enriched non-coding RNAs—regulate many of the core biological and pathogenic pathways altered in AD, including neuroinflammation, oxidative stress, synaptic dysfunction, neural plasticity, and amyloid/tau pathology. The company’s generated data demonstrated:

• Robust prediction models benchmarked against CSF, amyloid PET, and leading plasma biomarkers
• Identification of pre-symptomatic individuals at risk for progression to symptomatic AD
• Specificity for AD relative to other dementias, addressing a major barrier in early-stage diagnosis

This unique molecular signature reflects disease biology across the full AD continuum and provides a holistic, real-time window into brain health unprecedented among existing diagnostic modalities.  “The convergence of disease-modifying therapies and innovative blood-based diagnostics is creating a transformational moment in Alzheimer’s disease care,” added Andrew Lechleiter, Chief Executive Officer at Poplar Grove Investors, LLC. “Circular Genomics’ circRNA platform stands out for its ability to capture the complex biology of Alzheimer’s disease across multiple pathogenic pathways, which can provide clinicians with actionable insights, potentially even before memory and thinking issues emerge, that can fundamentally change patient care trajectories. The team’s progress in building a best-in-class biomarker signature, coupled with their strategic vision for market development, gives us tremendous confidence in their ability to execute and positively impact the lives of people affected by Alzheimer’s disease.”

Robust Data Generating a Potentially New Standard of Care

Building on the company’s recent presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, where findings demonstrated the platform’s potential to shift AD diagnosis from a reactive, late-stage process to an early, proactive, biologically grounded assessment, Circular Genomics is now positioned to deliver a new class of precision neurology diagnostics.

The company’s whole-blood transcriptomic models capture a broad landscape of disease-relevant circRNA signatures, enabling:

• Earlier detection before cognitive decline becomes clinically apparent
• More precise patient stratification for disease-modifying therapies
• Improved longitudinal monitoring of disease progression and therapeutic response
• Integration into primary care, expanding access to early intervention

These capabilities have the potential to fundamentally transform AD patient management—from identification of early disease biology and risk assessment to treatment selection and disease monitoring. By providing an accurate, accessible, and comprehensive molecular assessment of Alzheimer’s disease, Circular Genomics empowers physicians to identify patients at the earliest stages of the disease—even before symptoms appear—and match them with appropriate preventative interventions or disease-modifying therapies.

“Circular Genomics represents a rare opportunity to invest in a truly transformative diagnostic platform that addresses one of healthcare’s most pressing unmet needs,” said Joe Cook III, Managing Director at Mountain Group Partners. “The company’s circular RNA technology provides a fundamentally different and more comprehensive view of Alzheimer’s disease biology than existing biomarkers. Combined with the team’s world-class scientific expertise and the compelling clinical data they have generated; we believe Circular Genomics is uniquely positioned to become the leader in precision neurology diagnostics. We are honored to support their mission to enable earlier detection and better treatment outcomes for millions of patients.”

About Circular Genomics

Circular Genomics is the world-leading developer of circular RNA-based precision medicine tools, data and diagnostics for precision neurology and psychiatry. Leveraging exclusive licenses and pioneering technologies in circular RNA, Circular Genomics is aiming to reshape the standard of care for the early identification of neurological and psychiatric diseases such as Alzheimer’s disease, Parkinson’s disease, major depressive disorder, and bipolar disorder. Initial products include assays to assess and tailor optimal patient management care pathways resulting in more personalized and effective delivery of care. The company’s proprietary circRNA biomarker platform integrates advanced transcriptomics to generate sophisticated models of disease risk and progression, providing comprehensive insights into the multiple disrupted pathways critical to disease biology and pathology. For additional details, please visit www.circulargenomics.com. 

SOURCE Circular Genomics

“Like Sentry, but for AI Agents” – Funding led by Lightspeed Venture Partners will enable Raindrop to meet enterprise demand and become the default monitoring solution for AI agents.

SAN FRANCISCO, Dec. 1, 2025 — Raindrop, the monitoring platform for AI agents, announced $15M in seed funding led by Lightspeed Venture Partners. The funding will enable Raindrop to meet enterprise demand, and continue defining the frontier of production monitoring and issue detection for AI agents.

The round includes participation from leading AI companies including Figma Ventures, Vercel Ventures, founders of Replit (Amjad Masad and Michele Castata), Cognition (Walden Yan), Framer (Koen Bok and Joen van Dijk), Speak (Andrew Hsu), Notion (Akshay Kothari), and YC.

“AI agents are more capable than ever. They’re reasoning longer, using more tools, and connecting to MCP servers. Some agents now run autonomously for hours,” said Raindrop CEO Zubin Koticha. “Traditional testing methods, like evals, aren’t capable of handling the complexity of these long trajectories. This leaves engineering teams in the dark – unable to discover or track issues. Raindrop is the first monitoring platform to solve this problem.”

AI agents are increasingly entrusted with high-stakes tasks and deployed across critical sectors like healthcare and financial services; failures mean business-critical or even life-threatening issues. Recent headlines have been flooded by issues like ChatGPT encouraging users to stop taking medication or Air Canada being sued because their chatbot promised refunds they couldn’t honor.

Legacy monitoring tools for AI agents simply provided latency or token usage metrics. At best, they offered unreliable or generic metrics like toxicity or user sentiment. These metrics were not effective at revealing errors in AI agents.

Raindrop established the new standard for monitoring AI agent behavior: small, custom models that adapt to the unique shape of each AI product. This enables engineers to monitor signals that were previously invisible. For example, in addition to Raindrop’s default signals like “User Frustration,” customers can define custom signals like “UI Aesthetic Complaints” or “Agent Stuck in a Loop” and see incident rates over millions of events. Raindrop then triggers Sentry-style notifications when problems emerge.

To discover hidden issues, Raindrop’s AI agents work in the background to triage and investigate potential issue patterns. When a new issue is detected, like the agent encouraging toxic user behavior, Raindrop collects information on the issue and generates step-by-step explanations of what happened.

“We keep seeing AI engineering teams struggling with agent failures in production, and traditional evals are not really helping,” said Bucky Moore, Partner at Lightspeed. “We invested in Raindrop because they defined monitoring for AI agents. They made an early bet that monitoring would be the most critical part of building reliable agents, and they’ve been right. They’re growing fast as Raindrop is being embraced by some of the most forward-thinking engineering teams in AI. Lightspeed is thrilled to partner with Alexis, Ben, Zubin, and team to help them scale Raindrop into the default agent observability platform for enterprises and startups alike.”

Today Raindrop works with frontier AI customers processing millions of events each day to help quickly discover, monitor and resolve critical issues. Many of these teams use Raindrop Experiments, the first A/B testing platform for agents, to validate and iterate on solutions (tool, model or broader pipeline changes) and see if their fixes actually worked.

“Raindrop has been invaluable as we’ve been growing quickly,” said Evan Goldschmidt, CTO Tolan. “It’s critical for us to keep issue incidence below an acceptable threshold and become aware of any spikes. It’s like if we see an iOS crash report in Sentry, but for our AI capabilities.”

“Our founding team was building a coding agent ourselves and kept running into silent agent failures in production. When we did YC we saw everybody building agents in our batch had the same problem,” said Zubin Koticha, Raindrop’s CEO.

Raindrop was founded by Ben Hylak, Zubin Koticha and Alexis Gauba. Alexis and Zubin are second-time founders (previous company acquired by Coinbase); Ben was an engineer at Apple, before joining Apple’s elite Human Interface (HI) Design team where he worked for four years.

About Raindrop
Raindrop is an applied AI research company building “Sentry for AI agents” – monitoring infrastructure that catches when AI agents fail silently in production. Raindrop allows AI engineering teams to discover, track, and fix issues with their agents. Raindrop is backed by Lightspeed Venture Partners and other leading investors. https://www.raindrop.ai/

About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, Health, and Fintech sectors. Over the past 25 years, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 500 companies globally, including Abridge, Affirm, Anthropic, Cato Networks, Epic Games, Glean, Mistral, Moveworks, Navan, Netskope, Rubrik, Snap, Wiz and more. Lightspeed and its global team currently manage $30B in AUM across the Lightspeed platform, with investment professionals and advisors in the U.S., Europe, India, Israel, and Southeast Asia. www.lsvp.com

SOURCE Raindrop

CINCINNATI, Dec. 1, 2025 — Omni Fiber, a leading provider of high-speed fiber optic Internet services in the Midwest, today announced the closing of $150 million in incremental debt financing from Stonepeak Credit and Oak Hill Advisors (OHA), alongside an incremental $50 million equity investment from Oak Hill Capital. Additionally, Omni Fiber has closed a $10 million working capital facility with Republic Bank & Trust Company.

Founded in 2022 by management and Oak Hill Capital, Omni Fiber has invested over $400 million in building an XGS-PON fiber network and is on track to reach approximately 340,000 locations by the end of the year. The incremental financing from Stonepeak Credit and OHA, which follows a previous $150 million in debt financing from Stonepeak Credit announced in July 2024, will fund Omni Fiber’s continued expansion into more communities throughout the Midwest and Texas.

Omni Fiber provided service to its first community in December 2022 and now serves residential and business customers in approximately 60 small and mid-size communities in Ohio, Pennsylvania, Michigan, and Texas. Construction is in progress in approximately 25 communities, and network design and engineering activities are ongoing in many others.

Omni Fiber’s founding CEO, Darrick Zucco said, “We are grateful that the additional funds will accelerate our rapid expansion to bring fiber-optic connectivity to those who have been previously underserved. We welcome our new funding partners OHA and Republic Bank.”

Scott Baker, Managing Partner at Oak Hill Capital, added, “We are proud of our strong operating performance driven by the Omni Fiber management team and very pleased with the company’s continued growth. The Oak Hill additional equity investment, together with the incremental financing from debt partners, underscores our belief in the Omni Fiber business model.”

Ryan Roberge, Senior Managing Director at Stonepeak, added, “We continue to be impressed with the Omni Fiber team’s execution of their business plan. We are excited to upsize our investment and continue supporting the team and the high-quality fiber network they are deploying for customers in the Midwest.”

Greg Leveto, Portfolio Manager and Partner at OHA, said, “Omni Fiber has demonstrated strong execution and a clear commitment to expanding high-quality fiber broadband access in underserved communities. We are pleased to partner with Stonepeak and Oak Hill Capital Partners to support the company’s next phase of growth.”

About Omni Fiber
Founded in 2022, Omni Fiber is backed by Oak Hill Capital, one of the largest investment firms in the telecommunications industry. Based in Ohio, Omni Fiber is led by a leadership team with 100+ years of combined industry experience and provides 100% fiber-optic broadband Internet, TV, and Phone services to residential and business customers in the United States. Omni Fiber offers symmetrical speeds of up to 10 Gbps, no hidden fees, no data caps, Premium Wi-Fi included, local customer service, and competitive pricing. For more information, please visit www.omnifiber.com.

About Oak Hill Capital
Oak Hill Capital is a thematic, middle-market private equity firm focused primarily on investing in resilient, defensive growth-oriented services businesses in North America. The firm takes a systematic approach to identifying and building enduring franchises aligned with high conviction themes in (i) digital infrastructure; (ii) financial services; and (iii) essential services. Headquartered in New York City, with offices in Menlo Park and Stamford, over its ~40-year history, Oak Hill has invested in over 110 companies and has raised over $24 billion of initial capital commitments and co-investments since inception. For more information, please visit www.oakhill.com.

About Stonepeak Credit
Stonepeak Credit is the credit investing arm of Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets with approximately $80 billion of assets under management. Stonepeak Credit targets credit investments across the transportation and logistics, energy and energy transition, digital infrastructure, and social infrastructure sectors that provide essential services with downside protection, high barriers to entry and visible, recurring revenue generation. We seek to provide capital solutions that are flexible across the capital structure while generating cash yield through majority senior secured credit investments.

Stonepeak is headquartered in New York with offices in Houston, Washington, D.C., London, Hong Kong, Seoul, Singapore, Sydney, Tokyo, Abu Dhabi, and Riyadh. For more information, please visit www.stonepeak.com.

About OHA
Oak Hill Advisors (OHA) is a leading global credit-focused alternative asset manager with over 30 years of investment experience. OHA works with institutions and individuals and seeks to deliver a consistent track record of attractive risk-adjusted returns. The firm manages approximately $108 billion of capital across credit strategies, including private credit, high yield bonds, leveraged loans, stressed and distressed debt and collateralized loan obligations as of September 30, 2025. OHA’s emphasis on long-term partnerships with companies, sponsors and other partners provides access to a proprietary opportunity set, allowing for customized credit solutions across market cycles.
With over 400 experienced professionals across six global offices, OHA brings a collaborative approach to offering investors a single platform to meet their diverse credit needs. OHA is the private markets platform of T. Rowe Price Group, Inc. (NASDAQ – GS: TROW). For more information, please visit www.oakhilladvisors.com.

Omni Fiber Media Contact:
Andres Tovar
[email protected]
513-480-9610

SOURCE Omni Fiber

COSTA MESA, Calif., Dec. 1, 2025 — CerraCap Ventures and Impact Venture Capital today announced their merger to form CerraCap Impact Venture Capital (CIVC), creating one of the most globally connected venture platforms in the industry. The combined firm brings together an unmatched network of corporate customers, corporate investors, and strategic acquirers—positioning CIVC as a first-of-its-kind partner for founders needing rapid commercial validation and scalable enterprise adoption.

CIVC integrates CerraCap’s Sales & Scale™ commercialization engine with Impact Venture Capital’s Corporate Intelligence Platform™, a deep corporate development and investment network, spanning Fortune 500 companies and global strategic investors. Together, the platform gives startups accelerated access to enterprise customers, co-investors, corporate venture groups, and potential acquirers—shortening the path from early-stage innovation to revenue and ultimately to exit.

Operating at the intersection of enterprise AI, cybersecurity, digital health, national security, and advanced computing, CIVC will support founders building mission-critical technologies in sectors where commercial traction often depends on complex buyer landscapes. The firm’s combined global footprint across North America, Europe, India, and emerging markets enables founders to access international customer and investor networks far earlier in their journey.

CIVC’s leadership emphasized that the merger formalizes a long-standing collaborative relationship built on aligned values and complementary strengths.

Saurabh Ranjan, Co-Founder & Managing Partner, CerraCap Ventures, said:
“This merger creates a global institution built to deliver predictable, repeatable commercial outcomes for founders and investors.”

Saurabh Suri, Co-Founder & Managing Partner, CerraCap Ventures, added:
“Our cultural alignment and shared belief in value-creation beyond capital made this the natural next step.”

Eric Ball, Founding General Partner, Impact Venture Capital, noted:
“CIVC reflects the future of venture capital—global, integrated, and institutionally mature.”

Jack Crawford, Founding General Partner, Impact Venture Capital, stated:
“By unifying our platforms, we’re giving startups unparalleled access to corporate customers, investors, and strategic acquirers. Our goal is simple: shorten the time between innovation, adoption, and successful exit.”

CIVC and its partners are actively involved with the National Venture Capital Association’s CVC programs and serve as leaders in the Kauffman Fellows Corporate Venture Capital Special Interest Group, reinforcing the firm’s commitment to elevating corporate–startup collaboration across the global innovation ecosystem.

CerraCap Impact Venture Capital will continue building partnerships that connect founders directly to the enterprises and governments shaping the next decade of innovation.

More information is available at https://cerracapimpact.vc.

Contact: Nikki Arora, [email protected]

SOURCE CerraCap Ventures

LAVAL, QC, Dec. 1, 2025 – Morphocell Technologies Inc., a biotechnology company pioneering next-generation tissue therapeutics for organ replacement, today announced the completion of its US$50 million Series A financing following a US$10 million add-on led by Investissement Québec, the province’s leading economic development corporation, and CDP Venture Capital, part of Italy’s Cassa Depositi e Prestiti (CDP) group.

This financing extension builds upon the US$40 million Series A round closed in February 2024, which was led by Genson Capital, and marks an important milestone in Morphocell’s journey to transform the treatment of liver disease. The participation of two major institutional investors, both with long-term, mission-driven mandates, further strengthens the company’s foundation for growth, extending its operational runway to over three years.

“Since our initial Series A close, Morphocell has delivered remarkable progress across development, manufacturing and team expansion. The decision by Investissement Québec to deepen its commitment and by CDP Venture Capital to join our syndicate represents a powerful vote of confidence in our vision and execution. Their support further validates the global impact potential of our tissue-engineered therapies and strengthens our capacity to create transformative solutions to patients living with liver disease,” said Dr. Massimiliano Paganelli, CEO and co-founder of Morphocell Technologies.

Following the initial Series A close, Morphocell has grown to a team of 44 employees across its headquarters in the Greater Montréal Area and offices in Cambridge (Boston) and Toronto. The company’s vertically integrated operations span discovery, cell manufacturing, and preclinical development, reflecting its commitment to excellence in the regenerative medicine space.

A Strengthened Global Investor Syndicate

“Building on the first support from Impulsion PME in 2024, we are proud to continue our business relationship with Morphocell by reinvesting in its development through the new Fonds Impulsion and our own funds,” said Bicha Ngo, President and CEO of Investissement Québec. “The growing life-sciences industry is providing a global showcase for Québec talent and expertise and paving the way for the emergence of innovative solutions to multiple health challenges. Investissement Québec is delighted to help Morphocell achieve its ambitions.”

“We are particularly proud to be part of Morphocell’s journey, as it is a great example of how Italian world-class talent can innovate and drive impact on a global level.” said Alessandro Scortecci, Chief Direct Investments of CDP Venture Capital. “This marks our first investment in a Canadian biotech, a decision driven by our commitment to connect Italy with global innovation ecosystems. Our investment enables the establishment of Morphocell’s first European subsidiary, in Italy, which will build on the Country’s great talent, research capabilities, and industrial excellence, to strengthen the company’s global role in regenerative medicine.”

A Platform for the Future

With its Series A round now complete at US$50 million, Morphocell Technologies stands among the most well-funded private regenerative medicine companies in Canada. The financing strengthens Morphocell’s ability to:

• Advance its lead program, ReLiver^®, toward clinical proof-of-concept;
• Expand its manufacturing capacity and team of world-leading experts;
• Deepen its global collaborations and lay the foundation for future financing rounds.

Building on its strong presence in Québec and North America, Morphocell will now establish its first European subsidiary in Italy, a move that reflects the company’s Italian-founded roots and its commitment to contributing to Italy’s dynamic biotechnology sector. This expansion will serve as a strategic entry point into Europe, enabling Morphocell to build partnerships, access world-class talent and research infrastructure, and reinforce its position as a global leader in regenerative medicine.

“Morphocell’s goal has always been clear, to create revolutionary cell-based organ replacement therapies that cure patients,” added Dr. Paganelli. “This additional funding reinforces our shared conviction, with our investors, our partners, and our team, that we are building the future of regenerative medicine right here in Québec.”

“Our government is proud to support Morphocell Technologies in its growth. We want to help stimulate innovation in Quebec, which will play a decisive role in the evolution of modern medicine, particularly in regenerative medicine. This commitment is part of our desire to build a solid, dynamic, and forward-looking ecosystem where our companies can develop promising solutions for the health of tomorrow,” said Christine Fréchette, Minister of Economy, Innovation, and Energy.

About Morphocell Technologies

Morphocell Technologies is a Montreal-based regenerative medicine company developing stem cell–derived tissue and organ replacement therapies. Its proprietary iPSC-derived platform supports a broad pipeline of tissue-engineered solutions targeting severe organ dysfunctions, with liver disease as its first focus. Founded in 2018, Morphocell combines scientific excellence, clinical expertise, and cutting-edge manufacturing to bring next-generation regenerative therapies to patients worldwide.

To download images related to Morphocell, click here.

For more information, visit www.morphocell.com.

SOURCE Morphocell Technologies

• Financing led by Novartis Venture Fund and Forbion, with new investment from Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures
• Renewed backing from Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research

SAN DIEGO, Dec. 1, 2025 — Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders, today announced the completion of an oversubscribed $130 million Series B financing.

The round was led by Novartis Venture Fund and Forbion, with participation from new investors including Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures. Existing investors, including Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research, also participated, underscoring their continued conviction in the Protego approach. The round also reflects the active engagement of Ed Hurwitz, Executive Chairman, alongside Chris Weyrer, M.D., Ph.D., Principal at Vida Ventures and Acting Chief Business Officer of Protego, as the company advances its lead program.

Proceeds will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis, a rare and often fatal condition caused by protein misfolding that leads to organ damage, especially in the heart.

“We are deeply grateful for the steadfast support of our existing investors, who have believed in us through every stage, and we are pleased to welcome leading global investors to join us on this journey. Their confidence underscores the promise of our science and the urgency of our mission,” said Brent Warner, Chief Executive Officer of Protego Biopharma. “With the capital raised, we are positioned to advance PROT-001 into pivotal trials, moving closer to delivering the first disease-modifying therapy for AL amyloidosis and offering new hope to patients who currently face devastating outcomes.”

Protego’s therapeutic strategy is rooted in human genetics and a unique pharmacological chaperone mechanism. These small molecules act as cellular “guides,” ensuring proteins fold correctly. By stabilizing immunoglobulin light chains and preventing amyloid buildup, PROT-001 addresses disease at its root cause rather than simply managing symptoms. This approach represents a potential paradigm shift not only for AL amyloidosis, but also for a wide spectrum of protein misfolding disorders with profound unmet needs.

“Protego is advancing a highly differentiated approach with the potential to transform treatment for patients with AL amyloidosis,” said Tim Lohoff, PhD, Principal at Forbion. “By targeting the root cause of this severe disease, PROT-001 has the potential to deliver the first truly disease-modifying therapy in this indication. At Forbion, we invest in bold teams turning breakthrough science into tangible medical and commercial impact, and Protego exemplifies that vision.”

About Protego Biopharma
Protego Biopharma is a San Diego-based biotech company focused on developing small-molecule drugs that target protein misfolding pathways. By reprogramming cellular processes to restore proper protein function, Protego aims to treat rare and systemic diseases with precision and improved patient outcomes. For more information, visit www.protegobio.com.

SOURCE Protego Biopharma

SHANGHAI, Nov. 29, 2025 — On the afternoon of November 26, a major Grade 5 fire spread across multiple residential buildings in Wang Fuk Court in Tai Po, Hong Kong, causing severe casualties and drawing widespread public concern. In response, on November 28, Qiming Venture Partners made a donation of HK$3 million to the Tai Po Wang Fuk Court Aid Fund established by the Hong Kong SAR Government, to support affected residents and contribute to post-disaster reconstruction.

The Hong Kong SAR Government established the Tai Po Wang Fuk Court Aid Fund on November 27, with an initial allocation of HK$300 million, to coordinate social resources and fully carry out rescue and recovery support. The fund is also open to donations from the public, aiming to unite support from all walks of life to facilitate efficient aid distribution. Qiming Venture Partners responded promptly with this donation, to assist those affected while fulfilling its corporate social responsibility.

Qiming Venture Partners expresses our condolences to the families impacted by the major fire, and our deepest respect to the firefighters and rescue personnel at the frontline. We are grateful for their exceptional professionalism and selfless dedication which were evident throughout the crisis. Qiming hopes that its contribution will help alleviate the challenges faced by affected residents and support their swift return to normal life. Qiming also calls on more social forces to join in the relief efforts and contribute to the rebuilding of the affected communities.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

Many of our portfolio companies are today’s most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, HESAI, UBTech, WeRide, HyperStrong, Insta360, Unisound, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, AusperBio, Yuanxin Technology, Insilico Medicine, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others.

SOURCE Qiming Venture Partners

SINGAPORE, Nov. 27, 2025 — RockFlow, a Singapore-based AI-native fintech company backed by Lanchi Ventures, recently announced it has raised tens of millions of U.S. dollars in a new financing round. The round was led by a top-tier global digital financial services platform, with continued participation from Lanchi Ventures, Monolith Management, Forwest Capital, and Evergreen.

The fresh capital will be used to advance RockFlow’s proprietary financial AI, “Bobby,” and to accelerate the company’s global business expansion.

The financing follows the success of the RockAlpha AI Stock Trading Arena, a live-stock market stress test that benchmarked LLMs against real-world volatility. The initiative validated that RockFlow’s AI agent, Bobby, can autonomously execute complex trading strategies, marking a pivotal shift from passive AI assistance to active, agentic decision-making.

Underpinning this growth is a strong regulatory foundation. RockFlow’s parent group recently secured Type 1 (Dealing in Securities), Type 4 (Advising on Securities), and Type 9 (Asset Management) licenses from the Hong Kong Securities and Futures Commission (SFC).This milestone cements the platform’s ability to conduct regulated financial business in the international financial hub. Building on this regulatory milestone, RockFlow is poised to scale its business operations worldwide.

The company plans to extend its service offerings into new verticals, including brokerage, trusts, stablecoins, and digital banking. This supports RockFlow’s goal to build a comprehensive “All-in-One” platform that integrates traditional equities with emerging asset classes such as crypto, Real World Assets (RWA), and private equity.

“AI Agents are fundamentally reshaping the entry point and user experience for financial services,” said Vakee, Founder & CEO of RockFlow. “Our mission is to make investing simple, smart and fun. We are building an interface where complex, professional financial services become accessible and personalized through AI, all while adhering to strict global compliance standards.”

Lanchi Ventures commented: “We invest in AI that brings professional depth to mass markets. RockFlow’s ‘All-in-One’ platform and Bobby AI perfectly embody this vision. We remain bullish on their expertise at the intersection of finance and AI Agents as they scale globally.”

About RockFlow

RockFlow is a Singapore-headquartered AI fintech company dedicated to bringing a simple, fun, and intelligent investment experience to global investors through AI innovation. Since its inception, the company has received multiple rounds of investment from top-tier global USD funds and prominent tech founders, serving users in over 40 countries and regions.

RockFlow (https://rockflow.ai/) supports trading in US and HK stocks, and offers innovative features such as “Auto-DIP,” simplified options, and copy-trading. In 2025, the company officially launched Bobby, the world’s first financial AI Agent. Built on a proprietary AI Agents architecture and financial large models, Bobby allows users to interact via natural language to complete the full investment loop—from opportunity spotting and analysis to strategy construction and execution—making investing accessible and engaging for everyone.

SOURCE Lanchi Ventures